Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398810 | 0.86 | TSHR (0.41) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL25015371 | 0.85 | LMNA (0.51) | LMNAMAPTKMT2AMEN1EPHX2 | |
| SCHEMBL1968423 | 0.85 | CA12 (0.55) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL14691433 | 0.85 | MAPT (0.44) | LMNAMAPTKMT2AMEN1CASP3 | |
| Bromide SCHEMBL7614615 | 0.84 | CA12 (0.54) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| Iodide SCHEMBL5351689 | 0.84 | CA12 (0.54) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL1339677 | 0.83 | LMNA (0.48) | LMNAMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL28739371 | 0.81 | NPC1 (0.50) | LMNAMAPTPPARGALDH1A1HPGD | |
| SCHEMBL655688 | 0.80 | ALDH1A1 (0.56) | LMNAMAPTKMT2AMEN1CASP3 | |
| SCHEMBL8478730 | 0.78 | MAPT (0.50) | LMNAMAPTKMT2AMEN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | LMNA 4217/4885MAPT 2839/4885KMT2A 720/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | LMNA 4217/4885MAPT 2839/4885KMT2A 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.